In type 1 diabetic mice (induced by streptozotocin), systemic administration of AAV2/9 increased glomerular human VEGFC expression, ameliorating both albuminuria and increased glomerular permeability. The gene discussed is VEGFC; the disease is type 1 diabetes mellitus.